Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 95,900 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 95,900 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $21.02, for a total value of $2,015,818.00. Following the sale, the director owned 1,086,063 shares of the company’s stock, valued at $22,829,044.26. This represents a 8.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 1.4%

DYN stock opened at $20.61 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of -6.40 and a beta of 1.09. The business has a 50 day simple moving average of $18.43 and a two-hundred day simple moving average of $18.09.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the company posted ($1.05) earnings per share. Research analysts anticipate that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on DYN shares. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein increased their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. TD Cowen initiated coverage on Dyne Therapeutics in a research note on Friday. They set a “buy” rating on the stock. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Finally, Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning raised its position in Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after purchasing an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares in the last quarter. Hilton Head Capital Partners LLC purchased a new position in shares of Dyne Therapeutics during the first quarter valued at $26,000. Caxton Associates LLP increased its stake in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.